DX
Disease Management, Imaging, and Therapeutics
Friday, June 3, 2016: 2:00 PM-4:00 PM
Maryland B
2:00 PM
Patients of African Descent with Active RRMS Demonstrate Clinical and Radiologic Benefits with Alemtuzumab over 5 Years
Annette Okai, MD, Multiple Sclerosis Treatment Center of Dallas;
Keith R Edwards, MD, Multiple Sclerosis Center of Northeastern New York;
Brian Steingo, MD, Fort Lauderdale Multiple Sclerosis Center;
David H Margolin, MD, PhD, Genzyme, a Sanofi company;
Sourav Santra, PhD, Genzyme, a Sanofi company;
Mitzi J. Williams, MD, Multiple Sclerosis Center of Atlanta
2:15 PM
Patients with Active RRMS and Inadequate Response to Therapy at Baseline Show Durable Disability Improvement over 5 Years with Alemtuzumab: Care-MS II
Christopher LaGanke, MD, North Central Neurology Associates;
Aaron Boster, MD, OhioHealth Neurological Physicians;
Samuel F. Hunter, MD, PhD, Advanced Neurosciences Institute;
David H Margolin, MD, PhD, Genzyme, a Sanofi company;
Karthinathan Thangavelu, PhD, Genzyme, a Sanofi company;
Eva Havrdova, MD, PhD, Charles University in Prague;
Tina Walsh, n/a, Evidence Scientific
2:30 PM
Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with MS Using a Composite Measure of Disability
J Theodore Phillips, MD, PhD, FAAN, Baylor Institute for Immunology Research;
Amit Bar-Or, MD, FRCPC, Montreal Neurological Institute and Hospital, McGill University;
Ralf Gold, MD, St. Josef Hospital, Ruhr University;
Gavin Giovannoni, MBBCh, PhD, Queen Mary University of London, Blizard Institute;
Robert J Fox, MD, FAAN, Cleveland Clinic;
James Potts, PhD, Biogen;
Teesta Soman, MD, MBA, Biogen;
Jing L Marantz, MD, PhD, Biogen;
Jim B Lewin, PharmD, Biogen
2:45 PM
Natalizumab in Anti-JC Virus Seronegative Patients with Early Relapsing-Remitting Multiple Sclerosis: Interim Results from the STRIVE Study
Jai Perumal, MD, Judith Jaffe Multiple Sclerosis Center;
Roumen Balabanov, MD, Rush University Multiple Sclerosis Center;
Mary-Jean Fanelli, MD, Biogen;
Christophe Hotermans, MD, Biogen;
Allie McGinty, BA, Biogen;
Qunming Dong, MD, Biogen;
Laura J Balcer, MD, MSCE, New York University Langone Medical Center;
Steven Galetta, MD, New York University Langone Medical Center;
Jeffrey B English, MD, Multiple Sclerosis Center of Atlanta;
Robert J Fox, MD, FAAN, Cleveland Clinic;
Lily Lee, MD, Biogen;
Denise Campagnolo, MD, Biogen;
Mary k Lavy, md, Infusion Communications
3:00 PM
Five-Year Outcomes of Halt-MS: High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Severe Relapsing-Remitting Multiple Sclerosis
Richard A Nash, MD, Colorado Blood Cancer Institute;
George J Hutton, MD, Baylor College of Medicine;
Michael K Racke, MD, The Ohio State University Wexner Medical Center;
Uday Popat, MD, MD Anderson Cancer Center;
Steven M Devine, MD, The Ohio State University Wexner Medical Center;
George E Georges, MD, University of Washington;
Linda M Griffith, MD PhD, National Institute of Allergy and Infectious Diseases, National Institutes of Health;
Paolo A Muraro, MD, Imperial College;
Harry Openshaw, MD, City of Hope National Medical Center;
Peter Sayre, MD, University of California San Francisco;
Olaf Stuve, MD, University of Texas Southwestern Medical Center at Dallas;
Douglas L Arnold, MD, McGill University;
Kaitlyn C McConville, MS, Rho Federal Systems Division, Inc.;
Annette Wundes, MD, University of Washington;
George H Kraft, MD, University of Washington;
James D Bowen, MD, Swedish Medical Center;
James D Bowen, MD, Swedish Medical Center;
Richard A Nash, MD, Colorado Blood Cancer Institute
3:15 PM
Ocrelizumab Efficacy in PPMS Patients in the Presence/Absence of T1 Gadolinium-Enhancing Lesions at Baseline in a Phase III, Placebo-Controlled Trial
Jerry Wolinsky, MD, University of Texas Health Science Center at Houston;
Douglas L Arnold, MD, McGill University;
Amit Bar-Or, MD, FRCPC, McGill University;
Jérôme de Seze, MD, PhD, University Hospital of Strasbourg;
Gavin Giovannoni, MBBCh, PhD, FCP (Neurol., SA), FRCP, FRCPath, Queen Mary University of London;
Bernhard Hemmer, MD, Munich Cluster for Systems Neurology (SyNergy);
Kottil Rammohan, MD, University of Miami;
Peter Chin, MD, Genentech, Inc.;
Paulo Fontoura, MD, PhD, F. Hoffmann-La Roche Ltd.;
Hideki Garren, MD, PhD, F. Hoffmann-La Roche Ltd.;
Donna Masterman, MD, Genentech, Inc.;
Annette Sauter, MD, F. Hoffmann-La Roche Ltd.;
Xavier Montalban, MD, PhD, Hospital Vall d’Hebron University;
Ashley J Porter, PhD, Articulate Science
3:30 PM
3H-1, 2-Dithiole-3-Thione As a Novel Therapeutic Agent for the Treatment of Experimental Autoimmune Encephalomyelitis
Ping-Chang Kuo, Ph.D., Indiana University School of Medicine;
Dennis A Brown, Ph.D., Manchester University College of Pharmacy;
Barbara A Scofield, B.S., Indiana University School of Medicine;
I-Chen Yu, Ph.D., Indiana University School of Medicine;
Fen-Lei Chang, M.D., Ph.D., Indiana University School of Medicine;
Jui-Hung Yen, Ph.D., Indiana University School of Medicine
3:45 PM
The Effect of Fingolimod on Four Measures of Disease Activity in Patients with Relapsing–Remitting Multiple Sclerosis: A Meta-Analysis of the Phase 3 Freedoms Trials
Pavle Repovic, MD, PhD, Swedish Neuroscience Institute;
Göril Karlsson, PhD, Novartis Pharma AG;
Martin Merschhemke, MD, Novartis Pharma AG;
Dieter A Häring, PhD, Novartis Pharma AG;
Jeremy Bright, PhD, Oxford Pharmagenesis;
Terence Smith, PhD, Oxford Pharmagenesis
